enGene Therapeutics Inc. SEC filings ENGN
enGene Therapeutics Inc. has 267 filings in SEC EDGAR's recent list, going back to Jun 14, 2023. Its latest annual report, Form ARS, was filed on May 8, 2026 for the period ended Oct 31, 2025. The latest quarterly report (Form 10-Q) was filed on Sep 8, 2026, covering the quarter ended Jul 31, 2026. The most recent current report (Form 8-K) was filed on Sep 8, 2026 (results of operations). The company's fiscal year ends on October 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Other events
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 17, 2026 | Jul 17, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 16, 2026 | Jul 15, 2026 |
| 8-K/A |
Amended current report
Exit or restructuring costs, Officer or director change
|
Jun 18, 2026 | Jun 16, 2026 |
| 8-K |
Current report
Results of operations, Exit or restructuring costs, Officer or director change, Regulation FD disclosure, Other events
|
Jun 15, 2026 | Jun 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 10, 2026 | Jun 9, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure, Other events
|
May 7, 2026 | May 5, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Regulation FD disclosure
|
Apr 9, 2026 | Apr 7, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Mar 9, 2026 | Mar 9, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 9, 2026 | Mar 9, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Jan 21, 2026 | Jan 20, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 21, 2026 | Jan 20, 2026 |
| 8-K |
Current report
Results of operations
|
Dec 22, 2025 | Dec 22, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Nov 14, 2025 | Nov 12, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 12, 2025 | Nov 11, 2025 |
| 8-K |
Current report
Officer or director change
|
Oct 2, 2025 | Oct 2, 2025 |
| 8-K/A |
Amended current report
Officer or director change
|
Oct 2, 2025 | Jul 7, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 30, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Sep 11, 2025 | Sep 11, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 3, 2025 | Sep 3, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 8, 2025 | Jul 7, 2025 |
| 8-K |
Current report
Results of operations
|
Jun 12, 2025 | Jun 12, 2025 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 10, 2025 | Jun 10, 2025 |
| 8-K |
Current report
Material agreement, New debt
|
Jun 9, 2025 | Jun 4, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 4, 2025 | Jun 3, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 10, 2025 | Mar 10, 2025 |
| 8-K |
Current report
Material agreement
|
Dec 20, 2024 | Dec 20, 2024 |
| 8-K |
Current report
Material agreement, Results of operations, New debt
|
Dec 19, 2024 | Dec 19, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Oct 25, 2024 | Oct 24, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure, Other events
|
Oct 21, 2024 | Oct 16, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 26, 2024 | Sep 26, 2024 |
| 8-K |
Current report
Results of operations
|
Sep 10, 2024 | Sep 10, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 5, 2024 | Sep 5, 2024 |
| 8-K |
Current report
Officer or director change, Other events
|
Jul 24, 2024 | Jul 22, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jun 14, 2024 | Jun 14, 2024 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 15, 2024 | May 15, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 11, 2024 | Mar 11, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change, Regulation FD disclosure
|
Feb 14, 2024 | Feb 13, 2024 |
| 8-K |
Current report
Results of operations
|
Jan 29, 2024 | Jan 29, 2024 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Dec 28, 2023 | Dec 22, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Dec 21, 2023 | Dec 18, 2023 |
| 8-K |
Current report
Officer or director change
|
Dec 13, 2023 | Dec 13, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Nov 29, 2023 | Nov 27, 2023 |
| 8-K |
Current report
Officer or director change
|
Nov 9, 2023 | Nov 8, 2023 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change to shareholder rights, Change in control, Officer or director change, Bylaw or fiscal year change
|
Oct 31, 2023 | Oct 31, 2023 |
Showing 46 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ENGN (Nasdaq), ENGNW (Nasdaq)
- Fiscal year ends
- October 31
- Incorporated in
- Canada (Federal Level)
- Headquarters
- Saint-Laurent
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1980845
- Former names
- enGene Holdings Inc. (until Mar 9, 2026)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.